COSMO Pharmaceuticals Ownership
| COPN Stock | CHF 62.70 0.70 1.13% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
COSMO |
COSMO Stock Ownership Analysis
About 47.0% of the company shares are held by company insiders. The book value of COSMO Pharmaceuticals was currently reported as 28.23. The company last dividend was issued on the 1st of June 2022. Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. COSMO PHARM operates under Drug Manufacturers - Major classification in Switzerland and is traded on Switzerland Exchange. It employs 306 people. For more info on COSMO Pharmaceuticals SA please contact Alessandro LLM at 353 1 817 0370 or go to https://www.cosmopharma.com.COSMO Pharmaceuticals Outstanding Bonds
COSMO Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. COSMO Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most COSMO bonds can be classified according to their maturity, which is the date when COSMO Pharmaceuticals SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.